1921
Volume 102, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Four formulations of an investigational tetravalent dengue purified inactivated vaccine, administered as two doses one month (M) apart, were previously shown to be immunogenic and well-tolerated up to M13 of the phase I study NCT01702857. Here, we report results of the follow-up from M14 to year (Y) 3. One hundred healthy Puerto Rican adults, predominantly dengue virus (DENV)–primed, were randomized 1:1:1:1:1 to receive placebo or vaccine formulations: 1 μg/serotype/dose adjuvanted with aluminum, AS01 or AS03, or aluminum-adjuvanted 4 μg/serotype/dose. No serious adverse events occurred. Two medically-attended potential immune-mediated disease cases, vaccination unrelated, were reported (groups 1 µg+Alum and 1 µg+AS03). Of 14 instances of suspected dengue, none were laboratory confirmed. Geometric mean neutralizing antibody titers against DENV 1-4 waned from M14, but remained above pre-vaccination levels for DENV 1-3, with the highest values for group 1 µg+AS03: 1220.1, 920.5, 819.4, and 940.5 (Y2), and 1329.3, 1169.2, 1219.8, and 718.9 (Y3). All formulations appeared to be safe and immunogenic during the 3-year follow-up.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0461
2020-03-02
2020-06-06
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/5/tpmd190461.html?itemId=/content/journals/10.4269/ajtmh.19-0461&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2018. Dengue vaccine: WHO position paper–September 2018. Wkly Epidemiol Rec 93: 457476.
    [Google Scholar]
  2. Centers for Disease Control and Prevention. Dengue in Puerto Rico. Available at http://www.cdc.gov/dengue/about/inPuerto.html. Accessed December 3, 2018.
    [Google Scholar]
  3. Guy B, Noriega F, Ochiai RL, L’Azou M, Delore V, Skipetrova A, Verdier F, Coudeville L, Savarino S, Jackson N, 2017. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev Vaccines 16: 113.
    [Google Scholar]
  4. Sridhar S et al., 2018. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 379: 327340.
    [Google Scholar]
  5. Torresi J, Ebert G, Pellegrini M, 2017. Vaccines licensed and in clinical trials for the prevention of dengue. Hum Vaccin Immunother 13: 10591072.
    [Google Scholar]
  6. Martinez LJ et al., 2015. Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg 93: 454460.
    [Google Scholar]
  7. Schmidt AC et al., 2017. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg 96: 13251337.
    [Google Scholar]
  8. Diaz C et al., 2018. Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico. Am J Trop Med Hyg 98: 14351443.
    [Google Scholar]
  9. Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V, 2008. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods 153: 16.
    [Google Scholar]
  10. Thomas SJ et al., 2013. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 88: 7388.
    [Google Scholar]
  11. Moodie Z et al., 2018. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J Infect Dis 217: 742753.
    [Google Scholar]
  12. Sharp TM, Ryff KR, Santiago GA, Margolis HS, Waterman SH, 2019. Lessons learned from dengue surveillance and research, Puerto Rico, 1899–2013. Emerg Infect Dis 25: 15221530.
    [Google Scholar]
  13. Rosenberg R et al., 2018. Vital signs: trends in reported vectorborne disease cases–United States and Territories, 2004–2016. MMWR Morb Mortal Wkly Rep 67: 496501.
    [Google Scholar]
  14. Dejnirattisai W et al., 2016. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 17: 11021108.
    [Google Scholar]
  15. Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, Widman DG, Heise MT, de Silva AM, Baric RS, 2016. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. mBio 7: e01123e01116.
    [Google Scholar]
  16. Priyamvada L, Hudson W, Ahmed R, Wrammert J, 2017. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect 6: e33.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0461
Loading
/content/journals/10.4269/ajtmh.19-0461
Loading

Data & Media loading...

Supplemental figures and table

  • Received : 17 Jun 2019
  • Accepted : 20 Dec 2019
  • Published online : 02 Mar 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error